Liu Xingui, Zhao Fengting, Hu Linli, Sun Yingpu
Reproductive Medical Center of the First Affiliated Hospital, Zhengzhou University, Zhengzhou, Henan, People's Republic of China.
Clinical Laboratory, the First Affiliated Hospital, Zhengzhou University, Zhengzhou, Henan, People's Republic of China.
Onco Targets Ther. 2015 May 26;8:1239-43. doi: 10.2147/OTT.S81853. eCollection 2015.
This study explored the value of detection of human epididymis secretory protein 4 (HE4) and carbohydrate antigen 125 (CA125) from serum in diagnosis of early endometrial cancer of different pathological subtypes and discussed the mechanism of HE4 and CA125 in diagnosis. In this study, enzyme-linked immunosorbent assay and chemiluminescent immunoassay were used to detect HE4 and CA125 from serum in endometrial cancer and control groups. Besides, the concentration of HE4 and CA125 was compared in these two groups, and the expression of CA125 and HE4 and clinicopathological characteristics in patients with endometrial cancer were also analyzed. Compared with the control group, the expression of HE4 was much higher in serum of patients with endometrial cancer, while there was no obvious change in the expression of CA125. The threshold detection value was acquired by receiver operating characteristic analysis method, that is, 141.5 pmol/L and 54.5 U/L, respectively. When comparing the concentration of HE4 in patients with endometrial cancer at the early stage (stage I) with healthy people, the difference therein had statistical significance, but there was no obvious difference in CA125. HE4 and CA125 in diagnosis of endometrial cancer in the stages I and II were found with no statistically significant difference. The difference of HE4 in the stages II and III had statistical significance while the difference of CA125 had no statistical significance. The specificity of both HE4 and CA125 was 95%, and the sensitivity of HE4 to uterine papillary serous carcinomas was higher than that to endometrioid adenocarcinoma. Thus, the serum HE4 is much better than CA125 in detecting the endometrial cancer at an early stage.
本研究探讨了血清中人附睾分泌蛋白4（HE4）和糖类抗原125（CA125）检测在不同病理亚型早期子宫内膜癌诊断中的价值，并探讨了HE4和CA125的诊断机制。本研究采用酶联免疫吸附测定法和化学发光免疫测定法检测子宫内膜癌组和对照组血清中的HE4和CA125。此外，比较了两组中HE4和CA125的浓度，并分析了子宫内膜癌患者CA125和HE4的表达及临床病理特征。与对照组相比，子宫内膜癌患者血清中HE4的表达明显更高，而CA125的表达无明显变化。通过受试者工作特征分析方法获得阈值检测值，分别为141.5 pmol/L和54.5 U/L。比较早期（I期）子宫内膜癌患者与健康人血清中HE4的浓度，差异具有统计学意义，但CA125无明显差异。发现HE4和CA125在I期和II期子宫内膜癌诊断中的差异无统计学意义。II期和III期HE4的差异具有统计学意义，而CA125的差异无统计学意义。HE4和CA125的特异性均为95%，HE4对子宫乳头状浆液性癌的敏感性高于对子宫内膜样腺癌的敏感性。因此，血清HE4在早期检测子宫内膜癌方面比CA125要好得多。
